United states securities and exchange commission

Table of Contents
97
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has 
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
BIOGEN INC.
By:
/
S
/    M
ICHEL
 V
OUNATSOS
Michel Vounatsos
Chief Executive Officer
Date: February 1, 2018 

---

Table of Contents
98
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the 
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Name
  
Capacity
 
Date
/
S
/    M
ICHEL
 V
OUNATSOS
  
Director and Chief Executive Officer
(principal executive officer)
 
February 1, 2018
Michel Vounatsos
/
S
/    Jeffrey D. Capello
  
Executive Vice President and Chief
Financial Officer (principal financial
officer)
 
February 1, 2018
Jeffrey D. Capello
/
S
/    G
REGORY
 F. C
OVINO
Vice President, Finance, Chief
Accounting Officer (principal
accounting officer)
February 1, 2018
Gregory F. Covino
/
S
/    S
TELIOS
 P
APADOPOULOS
  
Director and Chairman of the Board of
Directors
 
February 1, 2018
Stelios Papadopoulos
/
S
/   
 
A
LEXANDER 
J
. 
D
ENNER
  
Director
 
February 1, 2018
 Alexander J. Denner
/
S
/    C
AROLINE
 D. D
ORSA
  
Director
 
February 1, 2018
Caroline D. Dorsa
/
S
/    N
ANCY
 L. L
EAMING
  
Director
 
February 1, 2018
Nancy L. Leaming
/
S
/    R
ICHARD 
C
. 
M
ULLIGAN
  
Director
 
February 1, 2018
Richard C. Mulligan
/
S
/    R
OBERT
 W. P
ANGIA
  
Director
 
February 1, 2018
Robert W. Pangia
/
S
/    B
RIAN
 S. P
OSNER
Director
February 1, 2018
Brian S. Posner
/
S
/    E
RIC
 K. R
OWINSKY
Director
February 1, 2018
Eric K. Rowinsky
/
S
/    L
YNN
 S
CHENK
Director
February 1, 2018
Lynn Schenk
/
S
/    S
TEPHEN
 A. S
HERWIN
Director
February 1, 2018
Stephen A. Sherwin

---

Table of Contents
F- 1
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
 
  
Page Number
Consolidated Statements of Income
  
F-2
Consolidated Statements of Comprehensive Income
F-3
Consolidated Balance Sheets
  
F-4
Consolidated Statements of Cash Flows
  
F-5
Consolidated Statements of Equity
  
F-6
Notes to Consolidated Financial Statements
  
F-9
Report of Independent Registered Public Accounting Firm
  
F-77

---

Table of Contents
F- 2
BIOGEN INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In millions, except per share amounts)
 
For the Years Ended December 31,
 
2017
2016
2015
Revenues:
Product, net
$
10,354.7
$
9,817.9 $
9,188.5
Revenues from anti-CD20 therapeutic programs
1,559.2
1,314.5
1,339.2
Other
360.0
316.4
236.1
Total revenues
12,273.9
11,448.8
10,763.8
Cost and expenses:
Cost of sales, excluding amortization of acquired intangible
assets
1,630.0
1,478.7
1,240.4
Research and development
2,253.6
1,973.3
2,012.8
Selling, general and administrative
1,935.5
1,947.9
2,113.1
Amortization of acquired intangible assets
814.7
385.6
382.6
Acquired in-process research and development
120.0
—
—
Collaboration profit (loss) sharing
112.3
10.2
—
Loss (gain) on fair value remeasurement of contingent
consideration
62.7
14.8
30.5
Restructuring charges
0.9
33.1
93.4
TECFIDERA litigation settlement charge
—
454.8
—
Total cost and expenses
6,929.7
6,298.4
5,872.8
Income from operations
5,344.2
5,150.4
4,891.0
Other income (expense), net
(215.4)
(217.4)
(123.7)
Income before income tax expense and equity in loss of
investee, net of tax
5,128.8
4,933.0
4,767.3
Income tax expense
2,458.7
1,237.3
1,161.6
Equity in loss of investee, net of tax
—
—
12.5
Net income
2,670.1
3,695.7
3,593.2
Net income (loss) attributable to noncontrolling interests, net
of tax
131.0
(7.1)
46.2
Net income attributable to Biogen Inc.
$
2,539.1
$
3,702.8 $
3,547.0
Net income per share:
Basic earnings per share attributable to Biogen Inc.
$
11.94
$
16.96 $
15.38
Diluted earnings per share attributable to Biogen Inc.
$
11.92
$
16.93 $
15.34
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Inc.
212.6
218.4
230.7
Diluted earnings per share attributable to Biogen Inc.
213.0
218.8
231.2
See accompanying notes to these consolidated financial statements.

---